News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

WuXi PharmaTech Co., Ltd. To Produce New Cancer Drug For Pharmacyclics, Inc. (PCYC)


11/15/2013 11:41:20 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

by Richard Daverman, PhD

November 15, 2013 -- WuXi PharmaTech announced that its CMO subsidiary, Shanghai SynTheAll Pharma, will produce commercial supplies of Imbruvica, a newly approved treatment for mantle cell lymphoma developed by Pharmacyclics. WuXi has been manufacturing the drug during its clinical trials. Imbruvica was approved by the US FDA as a second-line treatment earlier this week under a Breakthrough program that OK’d the drug after it completed a Phase II clinical trial. More details....

Stock Symbol: (NYSE: WX) (NSDQ: PCYC)

Help employers find you! Check out all the jobs and post your resume.

Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES